| Otimização da resposta imune vacinal utilizando a quimera recombinante F1F3 contra a leishmaniose visceral murina. |
|
2022 |
| Método imunoinformático como ferramenta na predição de vacina multicepas e multiepítopos de SARS-CoV-2 segura contra trombose trombocitopênica pós-vacinal. |
|
2022 |
| . Análise de homologia das proteínas S, E, M e N de cada variante do vírus SARS-CoV-2 a respeito da variante de Wuhan1 ancestral. Uma abordagem imunoinformática. |
|
2022 |
| A recombinant chimera contianing the C- and N- terminal moieties of the Nuclçsoide hydrolase (NH36) of Leishmania (L.) donovani in prophylaxis of mice agisnt Leishmania (L.) infantum infection. |
|
2014 |
| The One Health approach to visceral leishmaniasis. |
|
2013 |
| Vaccination against canine leishmaniosis in Brazil. Leishvet Symposium. WorldLeish 5 Congress. Porto de Galinhas, Pernambuco Brazil |
|
2013 |
| Vaccination with Nucleoside hydrolase (NH36) of L.(L.) donovani or its C-terminal portion (F3) in formulation with saponin prevents the deffective migration of Dendritic cells in murine experimental visceral leishmaniasis. |
|
2013 |
| Canine leishmaniosis: the disease, the problem and current approach to control and elimination. OIE-WSAVA symposium on Rabies and other disease risks from free-roaming dogs. |
|
2013 |
| The WSAVA One Health Committee: Positioning Companion Animals in Global Infectious Disease Surveillance. |
|
2011 |
| the WSAVA One Health Committee: Positioning Animals in Global infectious disease surveillance |
|
2011 |
| Mice vaccination with H3N8 inactivated by High Hydrostatic Pressure protect against experimental avian flu. |
|
2011 |
| Partial contribution of the B2 receptor of the kinin inflammation pathway in protection against murine visceral leishmaniasis by the C-terminal domain of Nucleoside hydrolase vaccine. |
|
2011 |
| Immunotherapy with the Leishmune®´s Nucleoside hydrolase DNA vaccine reduces infection and increases survival in a canine experimental model of visceral leishmaniasis. |
|
2011 |
| Increase of the adjuvant capability of Chiococca alba saponin by the increase of one sugar residue in the C-28 triterpene attached sugar chain. Effect on protection against visceral leishmaniasis. |
|
2011 |
| Cloning of the C-terminal Domain Peptides of Leishmania donovani Nucleoside Hydrolase (NH36) aiming the Identification of Antibody Epitopes.. |
|
2011 |
| Vaccination with the Leishmune®´s Nucleoside Hydrolase Maps the C-Terminal Domain as the Target of the Protective Immune Response |
|
2010 |
| Inactivation by Hydrostatic Pressure Preserves the Hemagglutinin and Neuraminidase Activities of the Avian Influenza Virus H3N8 |
|
2010 |
| Comparison the Prophylactic Potential of the Nucleoside Hydrolase Genetic Vaccine on Visceral Leishmaniasis Administered in Mice through the Intramuscular or the Intranasal Route |
|
2010 |
| Selecionada para comunicação oral: Comparison of adjuvant potential of a QS-21-containing saponin and the CA3 and CA4 saponins from Chiococca alba (L.) Hitch in murine vaccination agsitn visceral leishmaniasis with the FML antigen |
|
2010 |
| VACCINATION WITH THE LEISHMUNE®´S NUCLEOSIDE HYDROLASE MAPS THE C-TERMINAL DOMAIN AS THE TARGET OF THE PROTECTIVE IMMUNE RESPONSE |
|
2010 |
| A decrease in the incidence of human and canine visceral leishmaniasis in endemic areas of Brazil following vaccination of dogs with Leishmune® |
|
2009 |
| Development of a Second-Generation Vaccine against Dengue |
|
2009 |
| . Identification of the Leishmania donovani Nucleoside Hydrolase (NH36)-Peptide Sequences Containing Epitopes Involved in Protective Immune Response against Murine Visceral Leishmaniasis. |
|
2009 |
| Comparison of the Immunogenicity and Efficacy of the Leishmune® Prophylactic and Therapeutic Vaccines against Canine Early Experimental Infection with Leishmania chagasi. |
|
2009 |
| The FML-vaccine against canine visceral leishmaniasis: from the second generation to the synthetic vaccine. |
|
2008 |
| Cloning of the Nucleoside hydrolase of Leishmania donovani aiming the development of a synthetic vaccine against visceral leishmaniasis. |
|
2008 |
| The Nucleoside hydrolase DNA vaccine VR1012NH36 in prophylactic vaccination against mice tegumentar leishmaniaisis. |
|
2008 |
| Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis (CVL). |
|
2008 |
| Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis |
|
2007 |
| Vaccines for leishmaniasis in the fourthcoming 25 years |
|
2007 |
| Kinins generated aupon vaccination with the QS21 saponin-containing Leishmune(R) vaccine are partially responsibe for induction of protective immunity agaisnt visceral leishmaniasis |
|
2007 |
| Immunotherapy agasint canine visceral leishmanaisis with the saponin enriched Leishmune(R) vaccine |
|
2007 |
| Cross-protective efficacy of the prophylactic VR1012-NH36 Leishhmanaia-donovani DNA vaccine aginst cutaneous murine leishmaniasis by Leishmanaia amazonensis |
|
2007 |
| Structure-function studies of the novel CP05 saponin of Calliandra pulcherrima Benth adjuvant: assessment of monoterpene, glycidic fractions and triterpene in adjuvant function. |
|
2006 |
| Adjuvant effect of garlic extract with a DNA vaccine agasitn leishmania. |
|
2006 |
| Immunotherapy against visceral leishmaniasis with the nucleoside hidrolase-DNA vaccine of L donovani. Adjuvant effect of garlic EXtract. |
|
2005 |
| Phase I safety and immunogenicity trial of Leishmune ® in dogs of Brazilian endemic areas. |
|
2005 |
| The FML saponin vaccine against visceral leishmaniasis. Intranasal x subcutaneous administration in Balb/c mice. |
|
2005 |
| Leishmune ® vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. |
|
2005 |
| Immunotherapy against experimental canine visceral leishmaniasis with the industrialized FML-vaccine Leishmune (1mg saponin adjuvant). |
|
2005 |
| A DNA vaccine agaisnt cutaneous and visceral leishmaniasis. |
|
2005 |
| Immunotherpay against canine visceral leishmaniaisis with the FML vaccine |
|
2004 |
| Cross-protective efficacy of a prophylactic Leishmania donovani-DNA vaccine against visceral and cutaneous murine leishmaniasis |
|
2004 |
| Safety and Immunogenicity of an inactivated subunit vaccine against canine visceral leishmaniaisis. |
|
2004 |
| The FML vaccine on immunoprophylaxis and immunotherapy of canine visceral leishmaniasis |
|
2003 |
| Evaluation of the Nucleoside hydrolase 36 of Leishmania donovani as a recombinant or DNA vaccine against Leishmanai mexicana |
|
2003 |
| Long-lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante,RN) |
|
2002 |
| Impact of canine control on Brazilian kala-azar |
|
2001 |
| BCG,IL12 and saponins in the FML-vaccine against visceral leishmaniasis in mice |
|
2001 |
| Human kala-azar upon blood transfusion. |
|
2001 |
| IL12 and QuilA saponin adjuvants in the FML-vaccine against experimental visceral leishmaniasis |
|
2001 |
| The FML vaccine against murine and canine visceral leishmaniasis |
|
2001 |
| The FML-vaccine: a second generation candidate for vacination againt murine and canine visceral leishmaniasis. |
|
2001 |
| The FMLvaccine: a second generation candidate for vaccination against murine and canine visceral leishmaniasis |
|
2001 |
| QS-21 saponin adjuvant in the FMLvaccine against experimental visceral leishmaniasis. |
|
2001 |
| Immunoterapeuthic effect of the FML vaccine against experimental visceral leishmaniasis in Balb/c mice |
|
2000 |
| Immunotherapeutic effect of the FML-saponin vaccine in one canine case of visceral leishmaniasis (Sao Gonçalo, RJ) |
|
2000 |
| Inibição da internalização de promastigotas de L.(L.) donovani em macrófagos peritoneais murinos pela glicoproteína GP36 |
|
2000 |
| Human kala-azar upon blood transfusion |
|
2000 |
| The FML-ELISA assay in diagnosis of canine visceral leiahmaniasis in a recent outbreak at Araçatuba, SP. |
|
2000 |
| Comparative adjuvant effect of BCG and comercial saponins in the formulation of FML-vaccine against visceral leishmaniasis in mice |
|
2000 |
| Prevalencia de anticorpos anti-Leishmania chagasi através de técnicas sorológicas em amostras humans de General Carneiro, área urbana de Minas Gerais |
|
2000 |
| Prevalencia de anticorpos anti-Leishmania chagasi através de tecnicas sorologicas em amostras humanas de General Carneiro |
|
2000 |
| Analysisi of the adjuvant effect of Quillja brasiliensis saponins in the formulation of FML vaccine against visceral leiahmaniasis in mice |
|
2000 |
| Inhibition of Leishmania donovani promastigote internalization by the GP36 glycoprotein |
|
2000 |
| Occurrence of Leishmania donovani parasitemia in plasma of infected hamsters |
|
2000 |
| IL12 and saponin as adjuvants in the formulation of FML-vaccine against experimental visceral leishmaniasis |
|
2000 |
| Analysis of the hemolytic effect and in vivo toxicity of Quillaja brasiliensis saponins in the formulation of FML-vaccine against visceral leishmaniasis in mice |
|
2000 |
| Occurence of Leishmani donvani DNA in bone marrow of FML-seroreactive Brazilian Blood donors |
|
1999 |
| The FML vaccine against murine experimental visceral leishmaniasis. Comparison of the adjuvant effect of BCG and QuilA saponin |
|
1999 |
| Protective effect of the FML QuilA saponin vaccine against experimental canine kala-azar |
|
1999 |
| The FML elisa assay in serodiagnosis of canine visceral leishmaniasis of a recent outbreak in Araçatuba, Sao Paulo |
|
1999 |
| VACCINATION AGAINST CANINE KALA-AZAR WITH THE FML ANTIGEN AND rIEDEL dE HAEN SAPONIN IN AN ENDEMIC AREA (Sao Goncalo do Amaranto, RN) |
|
1999 |
| Cloning and characterization of Leishmania (L.) donovani inosine uridine nucleoside hydrolase |
|
1999 |
| Vacinacao contra o calazar canino com o antigeno FML de L. donovani e saponina no Rio Grande do Norte |
|
1999 |
| Vaccinataion Of Swiss Albino Mice Against Exprerimental Visceral Leishmaniasis With The Fml Antigen Of Leishmania Donovani |
|
1998 |
| Vacination Against Canine Kala-Azar With The Fml Antigen Of Leishmania Donovani And The Quila Saponin |
|
1998 |
| Investigação ultrasonografica e laboratorial em 7 pacientes soropositivos para leishmaniose atraves do FML-ELISA |
|
1998 |
| Vaccination against experimental kala-azar with the FML antigen of Leishmani donovani and QuilA saponin |
|
1998 |
| Vaccination against canine kala-azar with the FML antigen and Riedel De haen saponin in an endemic area (Sao Goncalo do Amaranto, RN) |
|
1998 |
| Ocurrence Of Leishmania Donovani Dna Inseroreactive Brazilian Blood Donors. |
|
1997 |
| Early Humoral Response In Mongrel Dog Vaccination With The Fml Antigen Of Leishmania Donovani In Combination With Saponin Adjuvants |
|
1997 |
| Prevalence Of Anti-Leishmania Donovani Antibodies Among Brazilian Blood Donors And Polytrasfused Hemodyalisis Patients.Correlation With Pcr |
|
1997 |
| Haemolytic activities of plant saponins and adjuvants Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani |
|
1997 |
| Comparative Ananlysisi Of The Adjuvant Activity Of The Abizia Saman Saponins On The Fml Antigen Of Leishmani Donovani |
|
1997 |
| Vaccination of balb/c mice with GP36 antigen of L. donovani and saponin |
|
1997 |
| The FMLELISA assay in diagnosis of canine visceral leishmaniasis |
|
1997 |
| Transmission Of Kala Azar By Blood Transfusion In Endemic Areas |
|
1996 |
| Exerimental murine Leishmania donovani infection: Imunoprotection by the fucose mannose ligand (FML). |
|
1994 |
| Surface glycoproteins of Leishmani donovani: GP36, the FML antigen present in pro and amastigotes is immunogenic for CB hamsters and recognized by human kala-azar antiserum |
|
1991 |
| Leishmania donovani (LD1S) Sudan glycoconjugates. Fatty acid composition and structure of LPPD glicidic moiety |
|
1989 |
| Leishmania donovani Lipopeptidephosphoglycan (LPPD) is not the major ligand for the promastigote internalization receptor on murine macrophages |
|
1989 |
| Leishmani donovani glycoconjugate ligands may be used for recognition and penetration of promastigotes into mouse macrophages |
|
1988 |
| Inhibition of Leishmania donovani promastigote internalization into murine macrophages by defined parasite glycoconjugate ligands |
|
1988 |
| Estudos dos gliccoconjugados de Leishmania donovani (LD1S) Sudan |
|
1987 |
